

# Hendrik Van Poppel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5964954/publications.pdf>

Version: 2024-02-01

161  
papers

9,159  
citations

57631

44  
h-index

42291

92  
g-index

238  
all docs

238  
docs citations

238  
times ranked

8343  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. <i>European Urology</i> , 2011, 59, 543-552.	0.9	910
2	Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). <i>Lancet, The</i> , 2012, 380, 2018-2027.	6.3	759
3	A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. <i>European Urology</i> , 2007, 51, 1606-1615.	0.9	572
4	Renal Function After Nephron-sparing Surgery Versus Radical Nephrectomy: Results from EORTC Randomized Trial 30904. <i>European Urology</i> , 2014, 65, 372-377.	0.9	448
5	BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP. <i>Journal of Urology</i> , 2000, 164, 1579-1582.	0.2	310
6	Renal Ischemia and Function After Partial Nephrectomy: A Collaborative Review of the Literature. <i>European Urology</i> , 2015, 68, 61-74.	0.9	274
7	European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. <i>European Urology</i> , 2020, 78, 21-28.	0.9	239
8	Positive Surgical Margin Appears to Have Negligible Impact on Survival of Renal Cell Carcinomas Treated by Nephron-Sparing Surgery. <i>European Urology</i> , 2010, 57, 466-473.	0.9	225
9	Treatment of Localised Renal Cell Carcinoma. <i>European Urology</i> , 2011, 60, 662-672.	0.9	198
10	Positive Surgical Margins After Nephron-Sparing Surgery. <i>European Urology</i> , 2012, 61, 757-763.	0.9	186
11	Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. <i>European Urology</i> , 2015, 67, 157-164.	0.9	180
12	Early Salvage Radiotherapy Following Radical Prostatectomy. <i>European Urology</i> , 2014, 65, 1034-1043.	0.9	171
13	Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer: Interim Results of a Prospective Randomized Trial. <i>Journal of Urology</i> , 1995, 154, 429-434.	0.2	152
14	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
15	PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA CAN ACHIEVE LONG-TERM TUMOR CONTROL. <i>Journal of Urology</i> , 1998, 160, 674-678.	0.2	141
16	Microscopic Vascular Invasion is the Most Relevant Prognosticator After Radical Nephrectomy for Clinically Nonmetastatic Renal Cell Carcinoma. <i>Journal of Urology</i> , 1997, 158, 45-49.	0.2	137
17	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 84-91.	0.9	136
18	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer – An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	0.9	132

#	ARTICLE	IF	CITATIONS
19	Key Steps in Conducting Systematic Reviews for Underpinning Clinical Practice Guidelines: Methodology of the European Association of Urology. <i>European Urology</i> , 2018, 73, 290-300.	0.9	128
20	Development of a standardised training curriculum for robotic surgery: a consensus statement from an international multidisciplinary group of experts. <i>BJU International</i> , 2015, 116, 93-101.	1.3	123
21	Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. <i>European Urology</i> , 2014, 66, 479-486.	0.9	121
22	Androgen receptor antagonists for prostate cancer therapy. <i>Endocrine-Related Cancer</i> , 2014, 21, T105-T118.	1.6	116
23	Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>European Urology</i> , 2021, 80, 703-711.	0.9	108
24	Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 357-368.	0.9	105
25	Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology</i> , 2016, 69, 728-733.	0.9	102
26	An Analysis of Radical Prostatectomy in Advanced Stage and High-Grade Prostate Cancer. <i>European Urology</i> , 2008, 53, 253-259.	0.9	101
27	Natural history of surgically treated high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 163.e7-163.e13.	0.8	101
28	Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. <i>European Urology</i> , 2019, 75, 176-183.	0.9	101
29	Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses. <i>European Urology</i> , 2017, 72, 64-75.	0.9	91
30	Gonadotropin-releasing hormone: An update review of the antagonists versus agonists. <i>International Journal of Urology</i> , 2012, 19, 594-601.	0.5	88
31	Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 142-150.	0.9	80
32	Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. <i>European Urology</i> , 2017, 71, 886-893.	0.9	77
33	Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. <i>European Urology</i> , 2020, 78, 661-669.	0.9	74
34	Neoadjuvant Hormonal Therapy Before Radical Prostatectomy Decreases the Number of Positive Surgical Margins in Stage T2 Prostate Cancer. <i>Journal of Urology</i> , 1995, 154, 429-434.	0.2	74
35	Surgical Metastasectomy in Renal Cell Carcinoma: A Systematic Review. <i>European Urology Oncology</i> , 2019, 2, 141-149.	2.6	73
36	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. <i>European Urology</i> , 2018, 74, 474-480.	0.9	72

#	ARTICLE	IF	CITATIONS
37	Renal Preservation and Partial Nephrectomy: Patient and Surgical Factors. <i>European Urology Focus</i> , 2016, 2, 589-600.	1.6	71
38	Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 1277-1284.	0.2	65
39	Vaccine Therapy in Patients with Renal Cell Carcinoma. <i>European Urology</i> , 2009, 55, 1333-1344.	0.9	62
40	Efficacy and safety of nephron-sparing surgery. <i>International Journal of Urology</i> , 2010, 17, 314-326.	0.5	61
41	Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. <i>European Urology</i> , 2018, 73, 436-444.	0.9	60
42	Is Surveillance an Option for the Treatment of Small Renal Masses?. <i>European Urology</i> , 2007, 52, 1323-1330.	0.9	57
43	Treatment of Erectile Dysfunction by Perineal Exercise, Electromyographic Biofeedback, and Electrical Stimulation. <i>Physical Therapy</i> , 2003, 83, 536-543.	1.1	56
44	Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>European Urology</i> , 2021, 79, 327-329.	0.9	54
45	A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 731-739.	2.6	51
46	EAU Policy on Live Surgery Events. <i>European Urology</i> , 2014, 66, 87-97.	0.9	50
47	Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019. <i>European Urology</i> , 2019, 76, 368-380.	0.9	48
48	Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?. <i>European Urology Oncology</i> , 2019, 2, 365-378.	2.6	47
49	Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 739-762.	1.9	38
50	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e605-e612.	0.9	37
51	Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. <i>European Urology Oncology</i> , 2020, 3, 209-215.	2.6	37
52	Benign Angiomyolipoma Involving the Renal Vein and Vena Cava as a Tumor Thrombus: Case Report. <i>Journal of Urology</i> , 1995, 153, 1205-1207.	0.2	36
53	The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016. <i>European Urology</i> , 2016, 70, 901-905.	0.9	36
54	The Role of Single Nucleotide Polymorphisms in Predicting Prostate Cancer Risk and Therapeutic Decision Making. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	35

#	ARTICLE	IF	CITATIONS
55	Parenchymal Volumetric Assessment as a Predictive Tool to Determine Renal Function Benefit of Nephron-Sparing Surgery Compared with Radical Nephrectomy. <i>Journal of Endourology</i> , 2016, 30, 114-121.	1.1	32
56	Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of <sup>68</sup> Ga-PSMA and <sup>11</sup> C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. <i>Journal of Urology</i> , 2020, 204, 296-302.	0.2	32
57	Chromosome abnormalities in benign prostatic hyperplasia. <i>Genes Chromosomes and Cancer</i> , 1994, 9, 227-233.	1.5	31
58	Lifestyle interventions to improve the quality of life of men with prostate cancer: A systematic review of randomized controlled trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 13-22.	2.0	30
59	Systematic Review of the Management of Local Kidney Cancer Relapse. <i>European Urology Oncology</i> , 2018, 1, 512-523.	2.6	30
60	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. <i>European Urology Focus</i> , 2021, 7, 574-581.	1.6	30
61	Radical cystectomy with or without urethrectomy?. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 47, 141-145.	2.0	26
62	Evaluation of degarelix in the management of prostate cancer. <i>Cancer Management and Research</i> , 2010, 2, 39.	0.9	25
63	Active Surveillance for Low-risk Prostate Cancer: Developments to Date. <i>European Urology</i> , 2015, 67, 646-648.	0.9	25
64	Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	1.3	25
65	Expression of a Distinct Set of Chemokine Receptors in Adipose Tissue-Derived Stem Cells is Responsible for In Vitro Migration Toward Chemokines Appearing in the Major Pelvic Ganglion Following Cavernous Nerve Injury. <i>Sexual Medicine</i> , 2013, 1, 3-15.	0.9	24
66	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	2.0	23
67	Conflict of Evidence: Resolving Discrepancies When Findings from Randomized Controlled Trials and Meta-analyses Disagree. <i>European Urology</i> , 2017, 71, 811-819.	0.9	23
68	Impact of neoadjuvant chemotherapy on short-term complications and survival following radical cystectomy. <i>World Journal of Urology</i> , 2019, 37, 1857-1866.	1.2	23
69	Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients. <i>European Urology Focus</i> , 2021, 7, 987-994.	1.6	23
70	Precancerous Lesions in the Kidney. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 136-165.	1.4	20
71	Chemoprevention of prostate cancer with nutrients and supplements. <i>Cancer Management and Research</i> , 2011, 3, 91.	0.9	20
72	Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. <i>European Urology Oncology</i> , 2019, 2, 589-596.	2.6	19

#	ARTICLE	IF	CITATIONS
73	Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 1543-1549.	1.2	19
74	Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer. <i>International Journal of Urology</i> , 2020, 27, 830-837.	0.5	19
75	Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. <i>BMC Urology</i> , 2012, 12, 8.	0.6	18
76	International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 97.	1.0	18
77	Oncological Outcomes of Metastasis-Directed Therapy in Oligorecurrent Prostate Cancer Patients Following Radical Prostatectomy. <i>Cancers</i> , 2020, 12, 2271.	1.7	18
78	Introducing PIONEER: a project to harness big data in prostate cancer research. <i>Nature Reviews Urology</i> , 2020, 17, 351-362.	1.9	18
79	Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. <i>European Journal of Cancer</i> , 2016, 69, 9-18.	1.3	17
80	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. <i>European Urology Focus</i> , 2018, 4, 369-375.	1.6	17
81	Prepubic Urethrectomy. <i>Journal of Urology</i> , 1989, 142, 1536-1537.	0.2	16
82	Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 960-967.	0.4	16
83	Degarelix as an Intermittent Androgen Deprivation Therapy for One or More Treatment Cycles in Patients with Prostate Cancer. <i>European Urology</i> , 2014, 66, 655-663.	0.9	16
84	Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in pT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 333-340.	0.4	16
85	Salvage high-intensity focused ultrasound versus salvage radical prostatectomy for radiation-recurrent prostate cancer: a comparative study of oncological, functional, and toxicity outcomes. <i>World Journal of Urology</i> , 2019, 37, 1507-1515.	1.2	16
86	Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. <i>European Urology</i> , 2020, 78, 779-782.	0.9	16
87	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 234.e13-234.e19.	0.8	15
88	The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting. <i>European Urology</i> , 2019, 76, 179-186.	0.9	15
89	Comparison of postoperative complications of ileal conduits versus orthotopic neobladders. <i>Translational Andrology and Urology</i> , 2020, 9, 2541-2554.	0.6	15
90	Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. <i>European Urology</i> , 2015, 67, 319-325.	0.9	14

#	ARTICLE	IF	CITATIONS
91	Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. <i>European Urology</i> , 2019, 76, 443-449.	0.9	14
92	Cardiovascular risk during hormonal treatment in patients with prostate cancer. <i>Cancer Management and Research</i> , 2011, 3, 49.	0.9	14
93	The t(1; 12)(p36;q13) in a Renal Oncocytoma. <i>Genes Chromosomes and Cancer</i> , 1996, 17, 136-139.	1.5	13
94	Changing Current Practice in Urology: Improving Guideline Development and Implementation Through Stakeholder Engagement. <i>European Urology</i> , 2017, 72, 161-163.	0.9	13
95	More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. <i>European Urology</i> , 2018, 74, 134-137.	0.9	13
96	Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. <i>Cancers</i> , 2021, 13, 583.	1.7	13
97	C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e17-239.e25.	0.8	13
98	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 5001-5001.	0.8	13
99	Current status and effectiveness of mentorship programmes in urology: a systematic review. <i>BJU International</i> , 2015, 116, 487-494.	1.3	12
100	Exploratory Subgroup Analyses of Renal Function and Overall Survival in European Organization for Research and Treatment of Cancer randomized trial of Nephron-sparing Surgery Versus Radical Nephrectomy. <i>European Urology Focus</i> , 2017, 3, 599-605.	1.6	12
101	Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma. <i>Scandinavian Journal of Urology</i> , 2020, 54, 493-499.	0.6	12
102	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. <i>Acta Oncologica</i> , 2021, 60, 1499-1506.	0.8	12
103	Tumour-related imaging parameters predicting the percentage of preserved normal renal parenchyma following nephron sparing surgery: a retrospective study. <i>European Radiology</i> , 2013, 23, 280-286.	2.3	11
104	Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. <i>Asian Journal of Urology</i> , 2014, 1, 40-45.	0.5	11
105	Biodistribution of Evans blue in an orthotopic <sc>AY</sc> rat bladder urothelial cell carcinoma model: implication for the improved diagnosis of non-muscle-invasive bladder cancer (<sc>NMIBC</sc>) using dye-guided white-light cystoscopy. <i>BJU International</i> , 2015, 116, 468-477.	1.3	11
106	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	0.9	11
107	Open and robotic radical prostatectomy. <i>Asian Journal of Urology</i> , 2019, 6, 125-128.	0.5	11
108	The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients. <i>PLoS ONE</i> , 2020, 15, e0244663.	1.1	11

#	ARTICLE	IF	CITATIONS
109	Nuclear medicine theranostics comes of age. <i>Lancet Oncology</i> , The, 2021, 22, 1497-1498.	5.1	11
110	The N-shaped orthotopic ileal neobladder: functional outcomes and complication rates in 119 patients. <i>SpringerPlus</i> , 2016, 5, 646.	1.2	10
111	Metastasectomy of oligometastatic urothelial cancer: a single-center experience. <i>Translational Andrology and Urology</i> , 2020, 9, 1296-1305.	0.6	10
112	Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 9522-32.	0.5	10
113	Nephron Sparing for Renal Cell Carcinoma: Whenever Possible?. <i>European Urology Focus</i> , 2016, 2, 656-659.	1.6	9
114	Comparison of Functional Outcome after Extended versus Super-Extended Pelvic Lymph Node Dissection during Radical Prostatectomy in High-Risk Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 280.	1.3	9
115	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e382-e394.	0.9	9
116	Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. <i>Prostate</i> , 2017, 77, 3-9.	1.2	8
117	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	0.9	8
118	Involvement of 12q12-13 is a nonrandom chromosome change in renal oncocytoma. , 1999, 24, 94-94.		7
119	Editorial Comment on: Tamoxifen as Prophylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150mg Monotherapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose-Response Study. <i>European Urology</i> , 2007, 52, 115.	0.9	7
120	Evaluation of conservative approach in the management of ureteroenteric strictures following radical cystectomy with Bricker ileal conduit: a single-center experience. <i>Scandinavian Journal of Urology</i> , 2016, 50, 439-444.	0.6	7
121	Comparison of Peri-operative and Early Oncological Outcomes of Robot-Assisted vs. Open Salvage Lymph Node Dissection in Recurrent Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 781.	1.3	7
122	The Cancer of the Bladder Risk Assessment (COBRA) score for estimating cancer-specific survival after radical cystectomy: external validation in a large multi-institutional cohort. <i>BJU International</i> , 2020, 126, 704-714.	1.3	7
123	Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 3177-3185.	1.2	7
124	Prepubic urethrectomy. <i>BJU International</i> , 2009, 103, 118-132.	1.3	6
125	Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. <i>BJU International</i> , 2017, 120, E52-E58.	1.3	6
126	The Percutaneous Operative Gastrostomy for Gastric Decompression in Major Urological Surgery. <i>Journal of Urology</i> , 1991, 145, 100-102.	0.2	5



#	ARTICLE	IF	CITATIONS
127	Evans blue-mediated white-light detection of non-muscle-invasive bladder cancer: A preclinical feasibility and safety study using a rat bladder urothelial cell carcinoma model. <i>Molecular and Clinical Oncology</i> , 2016, 5, 678-688.	0.4	5
128	Staging of prostatic carcinoma at 1.5-T MRI: correlation of a simplified MRI exam with whole-mount radical prostatectomy specimens. <i>British Journal of Radiology</i> , 2016, 89, 20160101.	1.0	5
129	Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 937.e1-937.e9.	0.8	5
130	Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: Challenges and opportunities. <i>European Journal of Cancer</i> , 2014, 50, 1957-1963.	1.3	4
131	Comparing the expression profiles of steroid hormone receptors and stromal cell markers in prostate cancer at different Gleason scores. <i>Scientific Reports</i> , 2018, 8, 14326.	1.6	4
132	The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review. <i>Minerva Urology and Nephrology</i> , 2018, 70, 109-125.	1.3	4
133	Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments. <i>World Journal of Urology</i> , 2021, 39, 399-406.	1.2	4
134	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. <i>European Urology Oncology</i> , 2022, 5, 285-295.	2.6	4
135	Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages â%¥ cT1b: a single institution, matched analysis. <i>Central European Journal of Urology</i> , 2018, 71, 48-57.	0.2	3
136	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	1.1	3
137	Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 527-541.	1.5	3
138	Open partial nephrectomy for complex tumours and >4 cm: Is it still the gold standard technique in the minimally invasive era?. <i>Archivos Espanoles De Urologia</i> , 2013, 66, 129-38.	0.1	3
139	Risk Stratification and Artificial Intelligence in Early Magnetic Resonance Imaging-based Detection of Prostate Cancer. <i>European Urology Focus</i> , 2022, 8, 1187-1191.	1.6	3
140	Harnessing New Media Tools in Patient Information. <i>European Urology</i> , 2018, 74, 685-687.	0.9	2
141	Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. <i>European Urology Oncology</i> , 2021, 4, 301-304.	2.6	2
142	Prognostic score predicts overall survival following complete urinary tract extirpation. <i>Scandinavian Journal of Urology</i> , 2020, 54, 70-79.	0.6	2
143	Uro-oncology in the era of social distancing: the principles of patient-centered online consultations during the COVID-19 pandemic. <i>Central European Journal of Urology</i> , 2020, 73, 260-264.	0.2	2
144	Should the pT2 tumor classification for renal cell carcinoma be subdivided according to tumor size?. <i>Nature Reviews Urology</i> , 2007, 4, 648-649.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Is nephron-sparing surgery as safe and effective as radical nephrectomy in patients with locally advanced RCC?. <i>Nature Reviews Urology</i> , 2008, 5, 296-297.	1.4	1
146	Clinically relevant genetic characterization of prostate tumors: How close are we to the goal?. <i>Korean Journal of Urology</i> , 2015, 56, 90.	1.2	1
147	Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. <i>Biomedicine Hub</i> , 2017, 2, 1-7.	0.4	1
148	European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. <i>European Urology</i> , 2020, 77, 397-399.	0.9	1
149	Re: Long-Term Outcome Following Three-Dimensional Conformal/Intensity-Modulated External-Beam Radiotherapy for Clinical Stage T3 Prostate Cancer. <i>European Urology</i> , 2008, 54, 1440-1441.	0.9	0
150	Re: The Role of Surgery in High-risk Localized Prostate Cancer. <i>European Urology</i> , 2014, 66, 387-389.	0.9	0
151	Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briens, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. <i>Eur Urol</i> 2018;74:84â€“91. <i>European Urology</i> , 2019, 75, e23-e24.	0.9	0
152	Radium-223 in patients with prostate specific antigen (PSA) progression and without clinical metastases following maximal local therapy: A pilot study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 40, 7.e9-7.e17.	0.8	0
153	Reply to Laura Evangelista and Egesta Lopciae™s Letter to the Editor re: Hendrik Van Poppel, RenA©e Hogenhout, Peter Albers, et al. Early Detection of Prostate Cancer in 2020 and Beyond: Facts and Recommendations for the European Union and the European Commission. <i>Eur Urol</i> 2021;79:327â€“9: Early Detection of Prostate Cancer in High-risk Patients with Negative Fusion Biopsy. <i>European Urology</i> , 2021, 80, e28-e29.	0.9	0
154	Radical Prostatectomy for Locally Advanced Prostate Cancer. , 2009, , 281-288.		0
155	Should we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? In Favour. <i>European Oncology and Haematology</i> , 2018, 14, 12.	0.0	0
156	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 302-302.	0.2	0
157	Reply to Takeshi Tanahashi™s Letter to the Editor re: Hendrik Van Poppel, Monique J. Roobol, Christopher R. Chapple, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. <i>Eur Urol</i> 2021;80:703â€“711: Would You Play a Russian Roulette-type Game of Prostate-specific Antigen Screening on Yourself?. <i>European Urology</i> , 2022, 81, e23-e24.	0.9	0
158	Title is missing!. , 2020, 15, e0244663.		0
159	Title is missing!. , 2020, 15, e0244663.		0
160	Title is missing!. , 2020, 15, e0244663.		0
161	Title is missing!. , 2020, 15, e0244663.		0